From Financial Modeling Prep: 2025-05-13 11:03:00

Piper Sandler updated its rating for NASDAQ:ANNX to Neutral, with the stock price slightly decreasing by approximately 1.98%. Annexon is progressing with key FDA meetings for Tanruprubart and initiating the FORWARD study. The company reported $263.7 million in cash, cash equivalents, and short-term investments, ensuring financial stability into 2026.



Read more at Financial Modeling Prep:: Annexon, Inc. (NASDAQ:ANNX) Stock Update and Finan…